INDIANAPOLIS (WISH) — Prostate cancer remains a significant health concern, being the second leading cause of death among men, particularly affecting black men. Early detection of prostate cancer is ...

One test could have prevented terminal prostate cancer, says patient - Research has shown that the use of the PSA test varies ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

ORLANDO, Fla. (Ivanhoe Newswire) - Prostate cancer is the second leading cause of death in men right behind heart disease. Patients with this cancer often don’t find out until the disease has advanced ...

The Prostate Cancer Foundation (PCF) is proud to announce the launch of an interactive website and downloadable guide, Somatic and Germline Genetic Testing for Patients with Advanced Prostate ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

(NewsNation) — The future of prostate cancer screening could be upon us. According to a new study published in the Cancer Research journal, early prostate cancer diagnoses can be made via a mere urine ...

eSpeaks' Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...

“New, more precise biomarkers than PSA can lead to earlier diagnosis and better prognoses for men with prostate cancer,” says Benson. “Moreover, it can reduce the number of unnecessary prostate ...

A new urology lab with advanced diagnostic testing is up and running at UPMC St. Margaret Hospital to deal with a slow but steady increase in the number of prostate cancer cases diagnosed each year.

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...